Kastner Randee J, Sicuri Elisa, Stone Christopher M, Matwale Gabriel, Onapa Ambrose, Tediosi Fabrizio
Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.
PLoS Negl Trop Dis. 2017 Sep 26;11(9):e0005934. doi: 10.1371/journal.pntd.0005934. eCollection 2017 Sep.
Lymphatic filariasis (LF), a neglected tropical disease (NTD) preventable through mass drug administration (MDA), is one of six diseases deemed possibly eradicable. Previously we developed one LF elimination scenario, which assumes MDA scale-up to continue in all countries that have previously undertaken MDA. In contrast, our three previously developed eradication scenarios assume all LF endemic countries will undertake MDA at an average (eradication I), fast (eradication II), or instantaneous (eradication III) rate of scale-up. In this analysis we use a micro-costing model to project the financial and economic costs of each of these scenarios in order to provide evidence to decision makers about the investment required to eliminate and eradicate LF.
METHODOLOGY/KEY FINDINGS: Costing was undertaken from a health system perspective, with all results expressed in 2012 US dollars (USD). A discount rate of 3% was applied to calculate the net present value of future costs. Prospective NTD budgets from LF endemic countries were reviewed to preliminarily determine activities and resources necessary to undertake a program to eliminate LF at a country level. In consultation with LF program experts, activities and resources were further reviewed and a refined list of activities and necessary resources, along with their associated quantities and costs, were determined and grouped into the following activities: advocacy and communication, capacity strengthening, coordination and strengthening partnerships, data management, ongoing surveillance, monitoring and supervision, drug delivery, and administration. The costs of mapping and undertaking transmission assessment surveys and the value of donated drugs and volunteer time were also accounted for. Using previously developed scenarios and deterministic estimates of MDA duration, the financial and economic costs of interrupting LF transmission under varying rates of MDA scale-up were then modelled using a micro-costing approach. The elimination scenario, which includes countries that previously undertook MDA, is estimated to cost 929 million USD (95% Credible Interval: 884m-972m). Proceeding to eradication is anticipated to require a higher financial investment, estimated at 1.24 billion USD (1.17bn-1.30bn) in the eradication III scenario (immediate scale-up), with eradication II (intensified scale-up) projected at 1.27 billion USD (1.21bn-1.33bn), and eradication I (slow scale-up) estimated at 1.29 billion USD (1.23bn-1.34bn). The economic costs of the eradication III scenario are estimated at approximately 7.57 billion USD (7.12bn-7.94bn), while the elimination scenario is projected to have an economic cost of 5.21 billion USD (4.91bn-5.45bn). Countries in the AFRO region will require the greatest investment to reach elimination or eradication, but also stand to gain the most in cost savings. Across all scenarios, capacity strengthening and advocacy and communication represent the greatest financial costs, whereas mapping, post-MDA surveillance, and administration comprise the least.
CONCLUSIONS/SIGNIFICANCE: Though challenging to implement, our results indicate that financial and economic savings are greatest under the eradication III scenario. Thus, if eradication for LF is the objective, accelerated scale-up is projected to be the best investment.
淋巴丝虫病(LF)是一种可通过大规模药物给药(MDA)预防的被忽视的热带病(NTD),是六种被认为有可能被根除的疾病之一。此前我们制定了一种LF消除方案,该方案假设MDA的扩大规模将在所有此前已开展MDA的国家继续进行。相比之下,我们之前制定的三种根除方案假设所有LF流行国家将以平均(根除方案一)、快速(根除方案二)或即时(根除方案三)的扩大规模速度开展MDA。在本分析中,我们使用微观成本核算模型来预测每种方案的财务和经济成本,以便为决策者提供关于消除和根除LF所需投资的证据。
方法/主要发现:成本核算从卫生系统角度进行,所有结果均以2012年美元(USD)表示。采用3%的贴现率来计算未来成本的净现值。对LF流行国家的前瞻性NTD预算进行了审查,以初步确定在国家层面开展消除LF计划所需的活动和资源。在与LF项目专家协商后,对活动和资源进行了进一步审查,并确定了一份详细的活动和必要资源清单,以及它们的相关数量和成本,并将其归类为以下活动:宣传与沟通、能力建设、协调与加强伙伴关系、数据管理、持续监测、监测与监督、药物分发和行政管理。还考虑了绘制和开展传播评估调查的成本以及捐赠药物和志愿者时间的价值。利用先前制定的方案和MDA持续时间的确定性估计,然后使用微观成本核算方法对在不同MDA扩大规模速度下中断LF传播的财务和经济成本进行建模。包括此前开展MDA的国家的消除方案估计成本为9.29亿美元(95%可信区间:8.84亿 - 9.72亿美元)。预计进入根除阶段需要更高的财务投资,在根除方案三(立即扩大规模)中估计为12.4亿美元(11.7亿 - 13.0亿美元),根除方案二(强化扩大规模)预计为12.7亿美元(12.1亿 - 13.3亿美元),根除方案一(缓慢扩大规模)估计为12.9亿美元(12.3亿 - 13.4亿美元)。根除方案三的经济成本估计约为75.7亿美元(71.2亿 - 79.4亿美元),而消除方案预计经济成本为52.1亿美元(49.1亿 - 54.5亿美元)。非洲区域的国家为实现消除或根除需要最大的投资,但在成本节约方面也将获得最大收益。在所有方案中,能力建设以及宣传与沟通占最大的财务成本,而绘制地图、MDA后监测和行政管理占比最小。
结论/意义:尽管实施具有挑战性,但我们的结果表明,在根除方案三下财务和经济节约最大。因此,如果以根除LF为目标,预计加速扩大规模是最佳投资。